News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,829 Results
Type
Article (41318)
Company Profile (265)
Press Release (688229)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204831)
Career Advice (2031)
Deals (35578)
Drug Delivery (128)
Drug Development (81504)
Employer Resources (173)
FDA (16499)
Job Trends (14979)
News (346787)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (45)
Adcomms (26)
Allergies (170)
Alliances (49579)
ALS (207)
Alzheimer's disease (1778)
Antibody-drug conjugate (ADC) (434)
Approvals (16870)
Artificial intelligence (646)
Autoimmune disease (276)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (742)
Cancer (5733)
Cardiovascular disease (460)
Career advice (1723)
Career pathing (41)
CAR-T (320)
CDC (56)
Celiac Disease (3)
Cell therapy (865)
Cervical cancer (46)
Clinical research (70691)
Collaboration (2023)
Company closure (5)
Compensation (1379)
Complete response letters (77)
COVID-19 (2739)
CRISPR (107)
C-suite (1095)
Cystic fibrosis (150)
Data (7688)
Decentralized trials (3)
Denatured (27)
Depression (158)
Dermatology (82)
Diabetes (581)
Diagnostics (6908)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (313)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91805)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119248)
Executive appointments (1073)
FDA (20165)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1699)
Gene editing (230)
Generative AI (55)
Gene therapy (699)
GLP-1 (1047)
Government (4724)
Grass and pollen (6)
Guidances (408)
Healthcare (18981)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (284)
Immuno-oncology (88)
Indications (183)
Infectious disease (3075)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16665)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (561)
Leadership (38)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (754)
Lymphoma (424)
Machine learning (59)
Management (59)
Manufacturing (1017)
MASH (183)
Medical device (13914)
Medtech (14023)
Mergers & acquisitions (20150)
Metabolic disorders (1478)
mRNA (198)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (406)
Neuropsychiatric disorders (104)
Neuroscience (3265)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (77)
Obesity (692)
Opinion (285)
Ovarian cancer (216)
Pain (250)
Pancreatic cancer (294)
Parkinson's disease (353)
Partnered (33)
Patents (590)
Patient recruitment (659)
Peanut (62)
People (59520)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22030)
Phase 2 (31146)
Phase 3 (23178)
Pipeline (8289)
Policy (311)
Postmarket research (2568)
Preclinical (9377)
Press Release (64)
Prostate cancer (292)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1053)
Real estate (5968)
Recruiting (70)
Regulatory (25326)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (176)
Series A (285)
Series B (210)
Service/supplier (11)
Sickle cell disease (110)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3637)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1085)
Venture capital (107)
Weight loss (444)
Women's health (122)
Worklife (20)
Date
Today (29)
Last 7 days (967)
Last 30 days (3094)
Last 365 days (30081)
2026 (11580)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32108)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (91)
Alaska (7)
Arizona (345)
Arkansas (14)
Asia (39626)
Australia (6497)
California (13050)
Canada (3712)
China (1313)
Colorado (558)
Connecticut (565)
Delaware (397)
Europe (85729)
Florida (1954)
Georgia (419)
Hawaii (3)
Idaho (62)
Illinois (1039)
India (88)
Indiana (593)
Iowa (23)
Japan (522)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1568)
Massachusetts (9299)
Michigan (358)
Minnesota (704)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3438)
New Mexico (29)
New York (3412)
North Carolina (1654)
North Dakota (8)
Northern California (6523)
Ohio (388)
Oklahoma (23)
Oregon (41)
Pennsylvania (2628)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5149)
Tennessee (209)
Texas (2066)
United States (46044)
Utah (391)
Vermont (1)
Virginia (311)
Washington D.C. (80)
Washington State (1047)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
729,829 Results for "qualigen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
October 6, 2025
·
4 min read
Press Releases
Qualigen Granted New Patents Covering 25 Countries
July 17, 2025
·
3 min read
Deals
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
Qualigen Therapeutics, Inc. announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company’s continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2).
May 30, 2024
·
5 min read
Press Releases
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
May 20, 2025
·
3 min read
Press Releases
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
May 2, 2025
·
3 min read
Press Releases
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
July 29, 2025
·
4 min read
Business
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Marizyme, Inc. (“Marizyme”, OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™.
April 16, 2024
·
4 min read
Press Releases
Qualigen Therapeutics, Inc. Announces management changes.
September 27, 2024
·
3 min read
Press Releases
Qualigen to participate in next funding round for NanoSynex
January 28, 2025
·
4 min read
Biotech Beach
Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
April 10, 2024
·
3 min read
1 of 72,983
Next
